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Severe hypertriglyceridaemia as a result of familial 
chylomicronaemia: the Cape Town experience
E D Pouwels, D J Blom, J C Firth, H E Henderson, A D Marais
Severe hypertriglyceridaemia (>15 mmol/l) is often encountered 
in clinical practice, where it is usually secondary to diabetes, 
alcohol excess, renal disease or medication. Familial 
chylomicronaemia (Fredrickson type I hyperlipoproteinaemia) is 
a rare cause of severe hypertriglyceridaemia. This autosomal 
recessive disorder affects about one in a million persons and is 
caused by defective plasma lipoprotein lipase (LPL) activity.1-3 
Rarely, familial chylomicronaemia is due to a complete 
(homozygous) deficiency of apolipoprotein C-II,2 which is the 
co-factor for LPL. A few cases of chylomicronaemia are caused 
by auto-antibodies to LPL.4
LPL is active at the capillary endothelium where it is bound 
to cell surface proteoglycans, from which it may be released 
by heparin.5 The primary function of LPL is the hydrolysis 
of triglycerides of very-low-density lipoproteins (VLDLs) 
and chylomicrons (CM), thereby delivering free fatty acids to 
muscle and adipose tissue for energy production or storage.6,7 
After ingestion and lipolysis of dietary triglyceride in the 
gut, there is complete absorption of non-esterified fatty 
acids into the enterocyte. The dietary fat is re-assembled 
into triglyceride, incorporated into CMs and released into 
the systemic circulation. These large particles scatter light, 
imparting opalescence in plasma from normal subjects in the 
postprandial state. The importance of LPL can be inferred 
from the limited postprandial rise of plasma triglyceride from 
a typical diet that contains about 100 mmol of triglyceride per 
day. The absence of LPL results in very retarded CM clearance 
evident as lipaemia.1-3 Hypertriglyceridaemia may be massive 
even in the fasting state, with plasma triglyceride typically 
more than 11 mmol/l (1 000 mg/dl).5,8 CM rise to the surface of 
the plasma when the sample is refrigerated overnight. Plasma 
VLDL levels are low because of the decreased availability of 
fatty acids for VLDL synthesis in the liver. HDL cholesterol 
levels are decreased because HDL is partly derived from the 
surface of chylomicrons through the action of LPL. Since 
CMs contain cholesterol, a massive increase will result in 
hypercholesterolaemia together with hypertriglyceridaemia.8
About 25% of patients with familial chylomicronaemia 
manifest complications before the age of 1 year, and the 
majority develop complications before the age of 10 years.3,9,10 
Some patients present for the first time during pregnancy.11,12 
Symptoms include severe abdominal pain, repetitive colicky 
pain or failure to thrive. Acute pancreatitis, often recurrent in 
LPL-deficient patients, can be lethal. On physical examination, 
eruptive xanthomata are frequently present (Fig. 1) and 
lipaemia retinalis can be observed.9 Although the clinical 
presentation is nonspecific, especially at a younger age,2,9 the 
plasma of the patients is always lipaemic.
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Lipoprotein lipase deficiency causes severe 
hypertriglyceridaemia due to chylomicronaemia, and leads 
to recurrent and potentially life-threatening pancreatitis. This 
disorder can only be managed by dietary fat restriction as 
drugs are ineffective.
We review the experience with familial chylomicronaemia 
in patients who attended the lipid clinics at Groote Schuur 
Hospital and Red Cross Children’s War Memorial Hospital 
in Cape Town. Criteria for inclusion were an initial plasma 
triglyceride concentration of >15 mmol/l and a typical type I 
Fredrickson hyperlipidaemia pattern on plasma lipoprotein 
electrophoresis. A total of 29 patients were seen over 25 
years. The mean age of presentation was 10 years, but ranged 
from 0 to 43 years. The modes of presentation differed: 
pancreatitis (N=16), eruptive xanthomata (N=2), coincidental 
detection of hypertriglyceridaemia (N=2), screening relatives 
(N=7), and after death from pancreatitis (N=1). Plasma 
triglycerides responded rapidly and dramatically to dietary 
fat restriction, and some patients sustained good control of 
the hyperlipidaemia. The onset of pancreatitis was earlier in 
patients of Indian ancestry, suggesting a genotype/phenotype 
interaction within this disorder. Genetic work-up indicated 
founder effects in the Afrikaner and Indian patients.
Lipaemic plasma should be taken seriously at all ages, 
and necessitates work-up at specialised clinics where the 
diagnosis of chylomicronaemia or type I hyperlipidaemia 
facilitates appropriate dietary management that can prevent 
pancreatitis.
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Our aim is to make South African medical practitioners 
aware of this rare, but simply treatable, disorder which has 
been found in several ethnic groups.
Methods
The records were reviewed of all patients with familial 
chylomicronaemia who attended the lipid clinics of Groote 
Schuur and/or Red Cross War Memorial Children’s hospitals 
in Cape Town between 1984 and 2006. The inclusion criteria 
were: initial plasma triglyceride concentration >15 mmol/l and 
the demonstration of practically only CM on electrophoresis 
(Fredrickson type I hyperlipidaemia).
Plasma lipid and lipoprotein concentrations were measured 
employing conventional automated spectrophotometric assays. 
In the majority of cases, genetic analysis of the LPL gene was 
also undertaken (and has been reported with international 
collaboration) that also determined LPL activity in a few cases.
Results
There were 29 patients from 21 kindreds. Ten of the subjects 
were Indian, 9 were coloured, 8 were of Afrikaner extraction, 
and 2 were black (1 Xhosa and 1 Zulu). Twenty-seven patients 
were from the Western Cape Province, 1 from KwaZulu-Natal, 
and 1 from Mauritius.
Ages at presentation varied from 2 weeks to 43 years, with 
a mean age of 10 years. Sixteen patients attended the clinic for 
the first time because of an attack of pancreatitis, 2 children 
presented with eruptive xanthomata, 1 male infant was 
diagnosed after death, 1 woman had incidentally discovered 
hypertriglyceridaemia, 1 boy was diagnosed following a stroke 
that was attributed to hypertriglyceridaemia, and 8 patients 
were diagnosed by family screening.
Nine of the 29 patients had undergone abdominal surgery: 
appendectomy and/or cholecystectomy. One patient had a 
modified Whipple’s procedure owing to intractable pain from 
recurrent pancreatitis. He was treated for exocrine pancreatic 
insufficiency and later became diabetic. Seven of the patients 
had diabetes, probably secondary to the repetitive attacks 
of pancreatitis. The 5 patients with hypertension may reflect 
the high prevalence of this disorder but may also suggest a 
relationship with hypertriglyceridaemia and/or diabetes.
All patients displayed a marked decrease in plasma 
triglycerides after dietary treatment. The mean worst 
triglyceride of 56±41 mmol/l fell to 10.9±8.8 mmol/l. No 
significant differences in triglyceride concentrations were seen 
between genders before and after treatment. Follow-up data 
are incomplete because patients with good dietary adherence 
generally obviate pancreatitis and remain well. Patients 
who adhered to diets restricting triglyceride to <10 g/d for 
short periods achieved fasting triglyceride concentrations of 
<6 mmol/l. Five of the 10 women were pregnant. Four had 
much increased plasma triglyceride concentrations despite 
meticulous diets, but fortunately escaped complications. The 
fifth patient had 21 hospital admissions for pancreatitis during 
her pregnancy, compared with 4 attacks before pregnancy and 
none in the 8 years thereafter. In this patient, life-threatening 
pancreatitis necessitated urgent caesarean section with a good 
outcome at 32 weeks’ gestation.
Four different LPL gene mutations were detected in this 
cohort of patients, with some segregation of mutations with 
ethnic groupings: 7 of the 8 Afrikaner patients (6 kindreds) 
were homozygous for the I194T mutation, while all 9 of the 
Indian patients (4 kindreds) were homozygous for the Q188R 
mutation (Table I).
Fig. 1. Eruptive xanthoma and lipaemia. Left: Small white papules visible 
on the pinna and cheek of this infant were due to familial lipoprotein lipase 
deficiency and resolved when appropriate diet was implemented. Right: 
Milky appearance of the plasma due to severe hypertriglyceridaemia in a 
patient with familial lipoprotein lipase deficiency.
Table I. Lipoprotein lipase mutations identified in various ethnic groups at the lipid clinics of Groote Schuur Hospital and 
Red Cross War Memorial Children’s Hospital
Mutation   Afrikaner   Mixed ancestry  Indian   Black
Q188R         0              0       9       0
I194T         7              2*       0       0
C418Y         0              1*       0       0
E421K†         0              1       0       0
102/Ins GGGCT        0              2       0       0
Unknown        1              5       1       2
* One patient was a compound heterozygote for the I194T and C418Y mutations.
† Found in heterozygous form in patient who died from pancreatitis in pregnancy.
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Phenotype/genotype relationships have not been 
characterised well in LPL deficiency. In our patient cohort, the 
I194T mutation was associated with a delayed presentation 
of pancreatitis when compared with the Q188R mutation. Of 
the 7 patients homozygous for the I194T mutation, 3 never 
had a history suggestive of pancreatitis, while 3 had their first 
attack after the age of 20 years, and only 1 of the 7 had an 
attack at a young age (3 months). In contrast, all the patients 
homozygous for the Q188R mutation were of Indian extraction 
and had their first attack of pancreatitis before or at the age of 
10 years. They had higher untreated plasma lipids as well as 
more frequent and more severe attacks compared with subjects 
with the I194T mutation. While there may be differences in 
lipoprotein metabolism according to the nature of the LPL 
mutation, diet might also have had an influence. A detailed 
analysis in 3 Afrikaners indicated a higher fat intake than in 
3 Indian patients, suggesting that other factors also play a 
role in the pathogenesis of pancreatitis. The coloured patients 
varied widely according to their age of presentation, age of 
first pancreatitis attack and lipid values. A brother and sister 
presumed to have Malayan ancestry had an insertion in exon 
3 (del 102; insertion GGGCT). The mutation(s) in the two black 
patients had not yet been determined.
Discussion
LPL deficiency causes massive accumulation of chylomicrons 
in plasma. The clinical presentation is heterogeneous 
and nonspecific, but the risk of pancreatitis is high and is 
remediable by dietary fat restriction. Our study documents one 
of the largest series of patients with familial chylomicronaemia 
managed at a single centre. The lipid clinic experience at 
Groote Schuur and Red Cross War Memorial Children’s 
Hospitals indicates that familial hyperchylomicronaemia 
is present in multiple ethnic groups and responds to diet. 
Additionally, there are founder effects in the Afrikaner and 
Indian populations. There may also be differences in the 
occurrence of pancreatitis in different genotypes or population 
groups.
Some additional comments can be made from our 
experience. Since one child died at 2 months of age and 
another required ventilation at the age of 3 months as a result 
of pancreatitis, chylomicronaemia should be borne in mind in 
infants who have lipaemic plasma. In older patients, abdominal 
pain with lipaemic plasma should point to chylomicronaemia 
as the cause, especially if no clear other cause is evident. The 
high number of appendectomies and cholecystectomies in 
our cohort underscores the importance of considering the 
diagnosis of (hypertriglyceridaemic) pancreatitis in patients 
with acute abdominal pain. Eruptive xanthomata often precede 
the abdominal pain, but are an unreliable clinical sign for the 
diagnosis of LPL deficiency. Every encounter with lipaemic 
plasma should therefore be taken seriously.
Not only a fatty diet provokes hypertriglyceridaemia 
and the attendant complication of pancreatitis. Acute 
pancreatitis is associated with oral contraceptive use in LPL-
deficient women.14 Marked chylomicronaemia with acute 
pancreatitis has been reported in LPL-deficient women 
during pregnancy,12,15-17 which could lead to death. Similarly, 
complications may occur with oestrogen replacement therapy.18
Successful therapy depends on expert dietetic advice and 
the patient’s adherence to the fat restriction. To achieve urgent 
reductions of hypertriglyceridaemia, adults are advised to 
consume approximately 10 g of triglycerides per day for 3 
days and to continue with 25 g per day. Regrettably, Groote 
Schuur Hospital no longer has a dedicated dietitian to ensure 
that the diet is appropriate in all its nutrients. This is especially 
important in the young. Since the restriction involves all 
kinds of fatty acids, care should be taken to include adequate 
amounts of essential fatty acids in the diet. Perceptions that the 
mono-unsaturated fatty acids in olive oil are healthy for such 
patients should be dispelled. Chylomicronaemia responds to 
dietary fat restriction within days and remains controlled with 
adherence to the diet. Inadvertent high fat intakes can occur as 
a result of poor labelling of foods. Children may unwittingly 
consume fatty foods or may be poorly adherent when 
rebellious during adolescence.
Additional management includes avoiding agents known to 
increase endogenous triglyceride, such as alcohol, oestrogens 
and retinoic acid derivatives. Diuretics and beta-adrenergic 
blocking agents have a lesser impact and may be used 
judiciously. The lipid-lowering drugs are not effective in 
familial LPL deficiency, as they do not correct the defective 
enzyme function.10 LPL is not replaced by a functional protein 
when fibrates are used, even though LPL is upregulated 
through the PPARα system. Orlistat causes malabsorption of 
dietary fat through inhibiting pancreatic lipase but is not a 
practicable agent as it causes steatorrhoea in doses required 
to make a meaningful difference. Gene therapy is awaited 
but may have limited duration of efficacy and may elicit 
an immune response to LPL that may appear foreign to the 
patient’s immune system.
There appears to be an increasing risk of pancreatitis 
according to plasma triglyceride concentrations, but high 
concentrations may sometimes be tolerated for weeks. 
Subclinical pancreatitis may cause significant harm to the 
pancreas and could lead to exocrine and/or endocrine 
insufficiency. The exact pathogenesis of pancreatitis is 
unclear. It is believed that the high CM concentration in the 
pancreatic microcirculation may impair oxygen delivery to 
the parenchymal cells that house enzymes able to digest 
biological tissue. Traces of pancreatic lipase may produce 
unesterified fatty acids, damaging endothelial cells and 
promoting thrombosis and infarction. Free radical damage to 
cells may perpetuate damage. Once significant tissue damage 
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has occurred, the process allows pancreatic enzymes to gain 
access to the systemic circulation so that the lungs and kidneys 
may also be injured. Fatty acids may bind calcium to cause 
hypocalcaemia.
In severe hypertriglyceridaemia, the diagnosis of pancreatitis 
by plasma enzyme activities often cannot be confirmed  
by spectrophotometric assays since high triglyceride 
concentrations interfere with laboratory tests.19 Other 
laboratory investigations can also be disturbed as a result of 
increased triglyceride levels, such as sodium, haemoglobin and 
bilirubin (artificially low).9,20,21 Accumulation of triglycerides 
in reticuloendothelial cells can lead to hepatomegaly, 
splenomegaly, and – rarely – also lymphadenopathy.
The best phenotypic test for chylomicronaemia is agarose 
gel electrophoresis. Chylomicronaemia may also be due to 
apoC-II deficiency that is also recessively inherited but may be 
clinically less severe than LPL deficiency and could respond to 
fresh plasma infusion. Definitive lipase assays are expensive, 
and are therefore not routinely available, but can discriminate 
between LPL deficiency, apoC-II deficiency and inhibitors for 
LPL. Secondary chylomicronaemia due to the inhibition of 
LPL by an antibody has also been seen in our clinic. LPL is a 
member of a family of lipases with catalytic activity in a serine 
protease-like hydrophobic pocket, including pancreatic lipase, 
hepatic lipase and endothelial lipase. About 100 different 
mutations have been identified in the human LPL gene, of 
which 20% occur in the non-coding regions and 80% in the 
coding regions.22,23 Most of the molecular defects are clustered 
in exon 5 (48.4%) and exon 6 (26.2%), spanning the catalytic 
pocket to account for about 75% of all mutations.22 Some 
mutations result in only moderate effect on LPL activity.24
Unusual and severe problems such as LPL deficiency 
are best managed at specialised tertiary centres that ought 
to serve patients from the public and private health care 
sectors. In the public health care sector, several patients 
have been admitted repeatedly for management of ‘acute 
abdomen’ before the aetiological diagnosis was made, but 
lipid-modifying medication was not prescribed as a result of 
supply restrictions of lipid-modifying drugs to lipid clinics. 
In the private health care sector, unnecessary admissions also 
occurred but, despite review of prescriptions, inappropriate 
medication was prescribed: simvastatin, atorvastatin and 
bezafibrate. Inappropriate attention was given to the 
hypercholesterolaemia, and the disproportionate rise in 
triglyceride concentration was not recognised as the clue to 
elevated chylomicron concentration. 
Evidence is emerging that chylomicronaemia may be 
atherogenic. The complication of diabetes mellitus with 
a resultant hepatic overproduction of very-low-density 
lipoprotein from the liver induces a Fredrickson type V 
hyperlipidaemia that may also contribute to atherosclerosis.
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